Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Exp Hepatol
Main Authors: Puri, Pankaj, Saraswat, Vivek A., Dhiman, Radha K., Anand, Anil C., Acharya, Subrat K., Singh, Shivaram P., Chawla, Yogesh K., Amarapurkar, Deepak N., Kumar, Ajay, Arora, Anil, Dixit, Vinod K., Koshy, Abraham, Sood, Ajit, Duseja, Ajay, Kapoor, Dharmesh, Madan, Kaushal, Srivastava, Anshu, Kumar, Ashish, Wadhawan, Manav, Goel, Amit, Verma, Abhai, Shalimar, Pandey, Gaurav, Malik, Rohan, Agrawal, Swastik
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2016
Assuntos:
Clinical Practice Guidelines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963318/
https://ncbi.nlm.nih.gov/pubmed/27493460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2016.07.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados